1. Home
  2. ONC vs IRM Comparison

ONC vs IRM Comparison

Compare ONC & IRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • IRM
  • Stock Information
  • Founded
  • ONC 2010
  • IRM 1951
  • Country
  • ONC Cayman Islands
  • IRM United States
  • Employees
  • ONC N/A
  • IRM N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • IRM Real Estate Investment Trusts
  • Sector
  • ONC Health Care
  • IRM Real Estate
  • Exchange
  • ONC Nasdaq
  • IRM Nasdaq
  • Market Cap
  • ONC 26.9B
  • IRM 24.1B
  • IPO Year
  • ONC N/A
  • IRM 1996
  • Fundamental
  • Price
  • ONC $231.99
  • IRM $97.09
  • Analyst Decision
  • ONC Strong Buy
  • IRM Strong Buy
  • Analyst Count
  • ONC 7
  • IRM 7
  • Target Price
  • ONC $326.43
  • IRM $122.57
  • AVG Volume (30 Days)
  • ONC 471.3K
  • IRM 1.6M
  • Earning Date
  • ONC 05-07-2025
  • IRM 05-01-2025
  • Dividend Yield
  • ONC N/A
  • IRM 3.23%
  • EPS Growth
  • ONC N/A
  • IRM N/A
  • EPS
  • ONC N/A
  • IRM 0.41
  • Revenue
  • ONC $4,175,868,000.00
  • IRM $6,265,575,000.00
  • Revenue This Year
  • ONC $860.73
  • IRM $10.29
  • Revenue Next Year
  • ONC $19.79
  • IRM $8.54
  • P/E Ratio
  • ONC N/A
  • IRM $236.86
  • Revenue Growth
  • ONC 51.16
  • IRM 11.04
  • 52 Week Low
  • ONC $141.31
  • IRM $72.33
  • 52 Week High
  • ONC $287.88
  • IRM $130.24
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • IRM 68.78
  • Support Level
  • ONC N/A
  • IRM $86.50
  • Resistance Level
  • ONC N/A
  • IRM $98.40
  • Average True Range (ATR)
  • ONC 0.00
  • IRM 2.49
  • MACD
  • ONC 0.00
  • IRM 1.28
  • Stochastic Oscillator
  • ONC 0.00
  • IRM 91.96

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About IRM Iron Mountain Incorporated (Delaware)Common Stock REIT

Iron Mountain Inc is a record management services provider. It is organized as a REIT. Majority of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business; Global Data Center Business; and Corporate and Other Business. It generates maximum revenue from Global RIM Business segment.

Share on Social Networks: